Video

Does Manufacturing Complexity Warrant Tech Investment, Or Detract From It?

Source: Bioprocess Online

In this segment of the Bioprocess Online Live event Bioprocess Manufacturing Analytics & Controls: Next Gen Technologies, Astellas Gene Therapies director of technical development Joshua Zibit discusses whether manufacturing complexity warrants investment in new analytical technologies, answers an audience question on scale-down validation, and reflects on in-sourcing versus outsourcing analytical development.

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)